DelveInsight’s “Cold Agglutinin Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cold Agglutinin Disease, historical and forecasted epidemiology as well as the Cold Agglutinin Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Cold Agglutinin Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cold Agglutinin Disease Market Forecast
Some of the key facts of the Cold Agglutinin Disease Market Report:
- The Cold Agglutinin Disease market size was valued USD 61 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- As per Danish study titled, “Epidemiology of Secondary Warm Autoimmune Haemolytic Anaemia- A Systematic review and Meta-Analysis” by Tranekær et al. (2021), although rare, AIHA is one of the most common forms of acquired hemolytic disorders with a prevalence of 9.5 per 100,000
- According to Norwegian study by Roth et al. (2019), states that Cold Agglutinin Disease is a complement-dependent, classical pathway-mediated immune hemolytic disease, accounting for 15-25% of AIHA
- As per DelveInsight’s analysis, in the year 2022, the total prevalent cases of Cold Agglutinin Disease were 12,879 cases in the 7MM, which are expected to rise during the study period
- 2019–2032
- In the year 2022, the total diagnosed cases of Cold Agglutinin Disease (CAD) were 4,398 cases in the US, which are expected to rise during the study period 2019–2032
- Key Cold Agglutinin Disease Companies: Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion, Incyte Corporation, and others
- Key Cold Agglutinin Disease Therapies: Pegcetacoplan, Iptacopan, Parsaclisib, sutimlimab, APL-2, Eculizumab, and others
- The Cold Agglutinin Disease epidemiology based on gender analyzed that Cold Agglutinin Disease frequency is usually more in females than in males
- The Cold Agglutinin Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cold Agglutinin Disease pipeline products will significantly revolutionize the Cold Agglutinin Disease market dynamics.
Cold Agglutinin Disease Overview
Cold agglutinin disease (CAD), is a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). In CAD, the red blood cells are destroyed prematurely and the rate of production of new cells in the bone marrow can no longer compensate for their loss.
Get a Free sample for the Cold Agglutinin Disease Market Report
https://www.delveinsight.com/sample-request/cold-agglutinin-disease-cad-market
Cold Agglutinin Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Cold Agglutinin Disease Epidemiology Segmentation:
The Cold Agglutinin Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Cold Agglutinin Disease
- Prevalent Cases of Cold Agglutinin Disease by severity
- Gender-specific Prevalence of Cold Agglutinin Disease
- Diagnosed Cases of Episodic and Chronic Cold Agglutinin Disease
Download the report to understand which factors are driving Cold Agglutinin Disease epidemiology trends @ Cold Agglutinin Disease Epidemiology Forecast
Cold Agglutinin Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cold Agglutinin Disease market or expected to get launched during the study period. The analysis covers Cold Agglutinin Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cold Agglutinin Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Cold Agglutinin Disease Therapies and Key Companies
- Pegcetacoplan: Apellis Pharmaceuticals
- Iptacopan: Novartis
- Parsaclisib: Incyte corporation
- SAR445088: Sanofi
Discover more about therapies set to grab major Cold Agglutinin Disease market share @ Cold Agglutinin Disease Treatment Market
Cold Agglutinin Disease Market Strengths
- Several organizations and companies like Cold agglutinin disease foundation and Sanofi Genzyme are raising awareness about the disease which can lead to increased patient pool
Cold Agglutinin Disease Market Opportunities
- Mild anemic patients because of CAD doesn’t have as such a pharmaceutical treatment option, so there is an unsaid need for the drugs in mild anemic patients
Scope of the Cold Agglutinin Disease Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Cold Agglutinin Disease Companies: Apellis Pharmaceuticals, Novartis, Incyte corporation, Sanofi, Alexion, Incyte Corporation,, and others
- Key Cold Agglutinin Disease Therapies: Pegcetacoplan, Iptacopan, Parsaclisib, sutimlimab, APL-2, Eculizumab, and others
- Cold Agglutinin Disease Therapeutic Assessment: Cold Agglutinin Disease current marketed and Cold Agglutinin Disease emerging therapies
- Cold Agglutinin Disease Market Dynamics: Cold Agglutinin Disease market drivers and Cold Agglutinin Disease market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Cold Agglutinin Disease Unmet Needs, KOL’s views, Analyst’s views, Cold Agglutinin Disease Market Access and Reimbursement
To know more about Cold Agglutinin Disease companies working in the treatment market, visit @ Cold Agglutinin Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Cold Agglutinin Disease Market Report Introduction
2. Executive Summary for Cold Agglutinin Disease
3. SWOT analysis of Cold Agglutinin Disease
4. Cold Agglutinin Disease Patient Share (%) Overview at a Glance
5. Cold Agglutinin Disease Market Overview at a Glance
6. Cold Agglutinin Disease Disease Background and Overview
7. Cold Agglutinin Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Cold Agglutinin Disease
9. Cold Agglutinin Disease Current Treatment and Medical Practices
10. Cold Agglutinin Disease Unmet Needs
11. Cold Agglutinin Disease Emerging Therapies
12. Cold Agglutinin Disease Market Outlook
13. Country-Wise Cold Agglutinin Disease Market Analysis (2019–2032)
14. Cold Agglutinin Disease Market Access and Reimbursement of Therapies
15. Cold Agglutinin Disease Market Drivers
16. Cold Agglutinin Disease Market Barriers
17. Cold Agglutinin Disease Appendix
18. Cold Agglutinin Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services